Date | Time | Source | Headline | Symbol | Company |
04/25/2024 | 1:52AM | Business Wire | Mundipharma erwirbt alle Vermögenswerte und Rechte an REZZAYO® (Rezafungin) und unterstreicht damit sein Engagement für das Management von Infektionskrankheiten und den Therapiebereich Spezialmedizin | | |
04/25/2024 | 1:52AM | Business Wire | Mundipharma acquiert tous les actifs et droits liés à REZZAYO® (rézafungine), renforçant ainsi son engagement continu dans la gestion des maladies infectieuses et les soins spécialisés | | |
04/25/2024 | 1:48AM | Alliance News | LONDON MARKET EARLY CALL: Stocks called down ahead of US GDP data | | |
04/25/2024 | 1:38AM | PR Newswire (Canada) | Wanhua Chemical Launches Barcelona R&D Center, Unveiling Signified Focus and Commitment in Europe and Beyond | | |
04/25/2024 | 1:38AM | PR Newswire (US) | Wanhua Chemical Launches Barcelona R&D Center, Unveiling Signified Focus and Commitment in Europe and Beyond | | |
04/25/2024 | 1:37AM | Alliance News | GET READY: AstraZeneca, Barclays, J Sainsbury, Relx, Weir at 0700 BST | | |
04/25/2024 | 1:37AM | Alliance News | Alliance News UK - start of day | | |
04/25/2024 | 1:32AM | GlobeNewswire Inc. | Crossject reports audited financial results for 2023 | EU:ALCJ | Crossject |
04/25/2024 | 1:32AM | GlobeNewswire Inc. | Crossject communique ses résultats financiers audités pour 2023 | EU:ALCJ | Crossject |
04/25/2024 | 1:32AM | GlobeNewswire Inc. | Crossject reports audited financial results for 2023 | EU:ALCJ | Crossject |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance | EU:SAN | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements | EU:SAN | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Huhtamäki Oyj’s Interim Report January 1–March 31, 2024: Improved operational profitability | TG:HUKI | Huhtamaki Oyj |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Atos reports first quarter 2024 performance | TG:AXI | Atos SE |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date | EU:ONWD | Onward Medical NV |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Atos publie sa performance du premier trimestre 2024 | EU:ATO | Atos SE |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | BGHL (GBP): NAV(s) | EU:BGHS | Boussard and Gavaudan Holding |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements | BIT:1SAN | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | BGHL (GBP): NAV(s) | LSE:BGHS | Boussard & Gavaudan Holding Limited |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance | BIT:SANF | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance | TG:SNW | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | BUREAU VERITAS - Strong start to the year; 2024 outlook confirmed | EU:BVI | Bureau Veritas |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Flow Traders Q1 2024 Trading Update | | |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance | BIT:1SAN | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Atos publie sa performance du premier trimestre 2024 | TG:AXI | Atos SE |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements | TG:SNW | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | BGHL (EUR): NAV(s) | EU:BGHL | Boussard And Gavaudan Holding Limited |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements | BIT:SANF | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | BUREAU VERITAS - Strong start to the year; 2024 outlook confirmed | TG:4BV | Bureau Veritas |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Atos reports first quarter 2024 performance | EU:ATO | Atos SE |